Current status of endoscopic submucosal dissection for early gastric cancer in Korea: role and benefits.


Journal

The Korean journal of internal medicine
ISSN: 2005-6648
Titre abrégé: Korean J Intern Med
Pays: Korea (South)
ID NLM: 8712418

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 07 11 2017
accepted: 31 12 2017
pubmed: 20 6 2018
medline: 30 1 2020
entrez: 20 6 2018
Statut: ppublish

Résumé

This study was aimed to investigate the current clinical status of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) in Korea based on a National Health Insurance (NHI) database between 2011 and 2014. The claims data of ESD for EGC in Korean NHI were reviewed using material codes of Health Insurance Review and Assessment Service between November 2011 and December 2014. The current clinical status was analyzed in terms of treatment pattern, in-hospital length of stay (LOS), total medical costs, and en bloc resection rate according to the hospital type. A total of 23,828 cases of ESD for EGC were evaluated. ESD was performed in 67.4% of cases in tertiary care hospitals, 31.8% in general hospitals, and 0.8% in hospitals, respectively. The median LOS was 5 days, and total median medical costs was approximately 1,300 US dollars. En bloc resection rate was 99%; 8.5% of cases underwent additional treatment within 90 days ESD, and 5.5% in 91 to 365 days after ESD. The clinical status was not significantly different according to the year and hospital type. A majority of ESD for EGC were performed in tertiary care hospitals in Korea. The clinical status showed excellent clinical outcomes and did not differ by the year and between the types of hospitals in Korea.

Sections du résumé

BACKGROUND/AIMS OBJECTIVE
This study was aimed to investigate the current clinical status of endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) in Korea based on a National Health Insurance (NHI) database between 2011 and 2014.
METHODS METHODS
The claims data of ESD for EGC in Korean NHI were reviewed using material codes of Health Insurance Review and Assessment Service between November 2011 and December 2014. The current clinical status was analyzed in terms of treatment pattern, in-hospital length of stay (LOS), total medical costs, and en bloc resection rate according to the hospital type.
RESULTS RESULTS
A total of 23,828 cases of ESD for EGC were evaluated. ESD was performed in 67.4% of cases in tertiary care hospitals, 31.8% in general hospitals, and 0.8% in hospitals, respectively. The median LOS was 5 days, and total median medical costs was approximately 1,300 US dollars. En bloc resection rate was 99%; 8.5% of cases underwent additional treatment within 90 days ESD, and 5.5% in 91 to 365 days after ESD. The clinical status was not significantly different according to the year and hospital type.
CONCLUSION CONCLUSIONS
A majority of ESD for EGC were performed in tertiary care hospitals in Korea. The clinical status showed excellent clinical outcomes and did not differ by the year and between the types of hospitals in Korea.

Identifiants

pubmed: 29921044
pii: kjim.2017.374
doi: 10.3904/kjim.2017.374
pmc: PMC6610182
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

785-793

Subventions

Organisme : National Evidence-based Healthcare Collaborating Agency

Commentaires et corrections

Type : CommentIn

Références

Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Cancer Res Treat. 2013 Jun;45(2):86-94
pubmed: 23864841
J Gastric Cancer. 2014 Jun;14(2):129-34
pubmed: 25061541
Gut Liver. 2015 Mar;9(2):174-80
pubmed: 25167804
Clin Epidemiol. 2014 Oct 24;6:395-404
pubmed: 25368532
Gut Liver. 2016 Sep 15;10(5):739-48
pubmed: 27172929
Cancer Res Treat. 2017 Apr;49(2):292-305
pubmed: 28279062

Auteurs

Sang Gyun Kim (SG)

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Da Hyun Lyu (DH)

National EvidenceBased Healthcare Collaborating Agency, Seoul, Korea.

Chan Mi Park (CM)

National EvidenceBased Healthcare Collaborating Agency, Seoul, Korea.

Na Rae Lee (NR)

National EvidenceBased Healthcare Collaborating Agency, Seoul, Korea.

Jiyoung Kim (J)

National EvidenceBased Healthcare Collaborating Agency, Seoul, Korea.

Youngju Cha (Y)

National EvidenceBased Healthcare Collaborating Agency, Seoul, Korea.

Hwoon-Yong Jung (HY)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH